Back to All Articles
You must be logged in to create a new articleBrowse articles with tag: Generic Drugs
All Articles
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Patexia Insight 152: Best Performing Brand and Generic Pharmas of 2022 (ANDA)
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More
Patexia Insight 151: ANDA Litigators Who Moved in the Last 12 Months
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by... Read More
Pedram Sameni
Aug 18, 2022
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman litigation... Read More
Mikele Bicolli
Aug 15, 2022
The FDA evaluates the generic versions of a drug and approves them only if studies show that it is... Read More